Effect of lactoferricin on fluoroquinolone susceptibility of uropathogenic Escherichia coli

Journal of Antibiotics

Volumn 62, Issue 2, 2009, Pages 109-111

  Longhi, Catia ^a   Marazzato, Massimiliano ^a   Conte, Maria Pia ^a   Iebba, Valerio ^a   Schippa, Serena ^a   Seganti, Lucilla ^a   Comanducci, Antonella ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Escherichia coli; Fluoroquinolones; Lactoferricin B; MIC; Resistance

Indexed keywords

AMOXICILLIN; BACTERIAL ENZYME; CEFALOTIN; CEFOTAXIME; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; DNA TOPOISOMERASE (ATP HYDROLYSING); ERYTHROMYCIN; GENTAMICIN; LACTOFERRICIN; LACTOFERRICIN B; NITROFURANTOIN; NORFLOXACIN; NOVOBIOCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BROTH DILUTION; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHYLOGENY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; URINARY TRACT INFECTION; UROPATHOGENIC ESCHERICHIA COLI;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FLUOROQUINOLONES; LACTOFERRIN; MICROBIAL SENSITIVITY TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; URINARY TRACT INFECTIONS;

ESCHERICHIA COLI;

EID: 62249214216     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.1038/ja.2008.22     Document Type: Article

References (19)

1. Nickel, J. C. Urinary tract infections and resistant bacteria. Rev. Urol. 9, 78-80 (2007).
2. Moreno, E. et al. Quinolone, fluoroquinolone and trimethoprim/sulfamethoxazole resistance in relation to virulence determinants and phylogenetic background among uropathogenic Escherichia coli. J. Antimicrob. Chemother. 57, 204-211 (2006).
3. Robicsek, A., Jacoby, G. A. & Hooper, D. C. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect. Dis. 6, 629-640 (2006).
4. Jenssen, H., Hamill, P. & Hancock, R. E. Peptide antimicrobial agents. Clin. Microbiol. Rev. 19, 491-511 (2006).
5. Valenti, P., Berlutti, F., Conte, M. P., Longhi, C. & Seganti, L. Lactoferrin functions: current status and perspectives. J. Clin. Gastroenterol. 38, 127-129 (2004).
6. Gifford, J. L., Hunter, H. N. & Vogel, H. J. Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell Mol. Life Sci. 62, 2588-2598 (2005).
7. van der Kraan, M. I. et al. Ultrastructural effects of antimicrobial peptides from bovine lactoferrin on the membranes of Candida albicans and Escherichia coli. Peptides 26, 1537-1542 (2005).
8. Fowler, C. E., Soothill, J. S. & Oakes, L. MICs of rifampicin and chloramphenicol for mucoid Pseudomonas aeruginosa strains are lower when human lactoferrin is present. J. Antimicrob. Chemother. 40, 877-879 (1997).
9. Qamruddin, A. O., Alkawash, M. A. & Soothill, J. S. Antibiotic susceptibility of Stenotrophomonas maltophilia in the presence of lactoferrin. Antimicrob. Agents Chemother. 49, 4425-4426 (2005).
10. Naidu, A. S. & Arnold, R. R. Lactoferrin interaction with Salmonellae potentiates antibiotic susceptibility in vitro. Diagn. Microbiol. Infect Dis. 20, 69-75 (1994).
11. Sanchez, M. S. & Watts, J. L. Enhancement of the activity of novobiocin against Escherichia coli by lactoferrin. J. Dairy Sci. 82, 494-499 (1999).
12. Vorland, L. H. et al. Interference of the antimicrobial peptide lactoferricin B with the action of various antibiotics against Escherichia coli and Staphylococcus aureus. Scand. J. Infect. Dis. 31, 173-177 (1999).
13. Chen, P. W., Ho, S. P., Shyu, C. L. & Mao, F. C. Effects of bovine lactoferrin hydrolysate on the in vitro antimicrobial susceptibility of Escherichia coli strains isolated from baby pigs. Am. J. Vet. Res. 65, 131-137 (2004).
14. Kanamaru, S. et al. Subtyping of uropathogenic Escherichia coli according to the pathogenicity island encoding uropathogenic-specific protein: comparison with phylogenetic groups. Int. J. Urol. 13, 754-760 (2006).
15. Johnson, J. R. & Stell, A. L. Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise. J. Infect. Dis. 72, 181-261 (2000).
16. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. 3rd edn. (Villanova, PA, 1993).
17. Moody, J. A. Synergy testing. Broth microdilution checkerboard and broth macrodilution methods. in Clinical microbiology procedures handbook, vol. 1 (ed Isenberg, H.D.) pp 5.18 1-14 (ASM Press, Washington, 1992).
18. Madurga, S., Sánchez-Céspedes, J., Belda, I., Vila, J. & Giralt, E. Mechanism of binding of fluoroquinolones to the quinolone resistance-determining region of DNA gyrase: towards an understanding of the molecular basis of quinolone resistance. Chembiochem. 9, 2081-2086 (2008).
19. Haversen, L. A., Engberg, I., Baltzer, L., Dolphin, G., Hanson, L. A. & Mattsby-Baltzer, I. Human lactoferrin and peptides derived from a surface-exposed helical region reduce experimental Escherichia coli urinary tract infection in mice. Infect. Immun. 68, 5816-5823 (2000).